New application of P-ATG in the preparation of drugs for preventing or treating psoriasis
By combining P-ATG with CD127, the activation of Th1 and Th17 is inhibited, the JAK/STAT5 signaling pathway is blocked, and the technical gap in psoriasis treatment is solved, and effective prevention and treatment of psoriasis is achieved.
Patent Information
- Application Number
- CN202311775911.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-21
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2043-12-21
AI Technical Summary
In the prior art, the application of P-ATG is mainly concentrated in the treatment of organ transplant rejection prevention, graft-versus-host disease and aplastic anemia of bone marrow transplantation, and lacks effective applications in the treatment of psoriasis.
P-ATG targets inhibit Th1 and Th17 activation by specifically binding to CD127, blocking the JAK/STAT5 signaling pathway, and is used to prevent or treat psoriasis.
In animal models of psoriasis, it significantly reduces the severity of the disease, inhibits inflammatory activation, improves skin symptoms, and provides a new form of drug for treating psoriasis.
Smart Images

Figure CN117752783B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biological medicines, and in particular to a new application of P-ATG in preparing medicines for preventing or treating psoriasis. Background Art
[0002] Anti-thymocyte globulin / anti-lymphocyte globulin (ATG / ALG) is a class of polyclonal antibody drugs targeting human T lymphocytes (see literature: X, FLACHER M, LEMAUFF B, et al. Mechanisms involved in antithymocyte globulinimmunosuppressive activity in a nonhuman primate model [J]. Transplantation, 2001, 71(3): 460-468, Literature: FENG X, KAJIGAYA S, SOLOMOU EE, et al. Rabbit ATG butnot horse ATG promotes expansion of functional CD4+CD25highFOXP3+regulatory Tcells in vitro[J].Blood,2008,111(7):3675-3683, and literature: LAN F, ZENG D, HIGUCHIM, et al. Predominance of NK1.1+TCRαβ+or DX5+TCRαβ+T Cells in mice conditionedwith fractionated lymphoid irradiation protects against graft-versus-hostdisease:"natural suppressor"Cells[J].J Immunol, 2001, 167(4): 2087-2096), mainly through complement dependent cytotoxicity (CDC) to kill activated T lymphocytes (see literature: MOHTY, M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond [J]. Leukemia, 2007, 21(7): 1387-1394, and literature: LECHNER K, JAGER U. How I treat autoimmune hemolytic anemias in adults [J]. Blood, 2010, 116(11): 1831-1838), to achieve the inhibition of T lymphocyte function in the peripheral blood circulation system (see literature: GENESTIERL, FOURNEL S, FLACHER M, et al.Induction of Fas(Apo-1,CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins[J].Blood,1998,91(7):2360-2368, and literature: Malcovati L,Régis Peffault de Latour,RisitanoA.Aplastic anemia&MDS International Foundation(AA&MDSIF):Bone Marrow FailureDisease Scientific Symposium 2010[J].Leukemia research,2010,35(3):291-294). .
[0003] The preparation principle and mechanism of action of ATG / ALG are similar. Both use human thymocytes or lymphocytes to immunize healthy horses, rabbits, pigs and other animals. After the immunized animals produce specific antibodies against thymocytes or lymphocytes, the animal plasma / serum is collected and separated, purified and refined (see literature: Brennan DC. Faith supported by reason: mechanistic support for the use of polyclonal antibodies in transplantation. [J]. Transplantation, 2003, 75 (5): 577-578, and literature: Yu Jian, Wu Di, Zai Jiamin, et al. Study on purification of anti-human T cell porcine immunoglobulin by low temperature ethanol method [J]. Advances in Microbiology and Immunology, 2008, 36 (3): 42-44). Its dosage form is mostly liquid or lyophilized preparation, and the main component is animal-derived IgG.
[0004] Anti-human T Lymphocyte Porcine Immunoglobulin (P-ATG) is an ATG / ALG drug independently developed in my country in the 1970s. It fills the gap of such products in my country and has the advantages of low price, strong immunosuppressive effect and few drug side effects (see literature: Chen Shanhua, Shi Liangru, Chen Jing. Research on the trial production of anti-lymphocyte globulin (ALG Suis) [J]. Journal of Wuhan Medical College, 1978(04):56-59).
[0005] P-ATG is mainly used clinically for the prevention and treatment of organ transplant rejection, the prevention of graft versus-host disease (GVHD) in bone marrow transplantation, and the treatment of severe aplastic anemia (SAA), and has fewer uses. Summary of the invention
[0006] Based on this, it is necessary to provide new applications of P-ATG in the preparation of drugs for the treatment of psoriasis, which can not only expand the new applications of P-ATG in the preparation of drugs for the treatment of psoriasis.
[0007] The present invention adopts the following technical solution:
[0008] The present invention provides a new application of P-ATG in preparing a medicine for preventing or treating psoriasis.
[0009] In particular, the P-ATG can specifically bind to CD127.
[0010] In particular, the P-ATG can target and inhibit the activation of Th1 and Th17.
[0011] In particular, the psoriasis is psoriasis vulgaris, pustular psoriasis, erythrodermic psoriasis or arthritic psoriasis.
[0012] In particular, the P-ATG can block the JAK / STAT5 signaling pathway and inhibit the activation of Th17.
[0013] The present invention can also provide a drug for preventing or treating psoriasis, wherein the drug comprises P-ATG.
[0014] The dosage form of the drug is at least one of a liquid preparation, a lyophilized powder, a spray, an ointment, and a gel.
[0015] Compared with the prior art, the core advantages of the present invention are:
[0016] The present invention has found through a large number of experiments that P-ATG can effectively reduce the disease severity of the classic animal model of psoriasis, can specifically bind to CD127 in vitro, and inhibit the inflammatory activation of Th1 and Th17, thereby achieving the effect of preventing or treating psoriasis. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1The results of P-ATG treatment on the ear skin of mice with imiquimod-induced psoriasis and the skin thickness (n=5, **P<0.01); A is a representative photo of the ear skin of mice in the control group (Ctrl), imiquimod-induced psoriasis model group (IMQ+IgG) and P-ATG treatment group (IMQ+IP-ATG) on the 7th day of modeling; B is the measurement results and statistical analysis of the ear thickness (EAR thickness) of mice in the psoriasis model group and the P-ATG treatment group from 0 to 7 days after modeling;
[0018] Figure 2 The PASI clinical score results of P-ATG-treated imiquimod-induced psoriasis mice (n=5, ***P<0.001); wherein, A is the score (Score) result of mouse ear skin thickness (Thickness) within 0 to 7 days after modeling (Days after adminstration), B is the score (Score) result of mouse ear skin redness (Erythma) within 0 to 7 days after modeling (Days after adminstration), C is the score (Scaling) result of mouse ear skin within 0 to 7 days after modeling (Days after adminstration), and D is the cumulative score result of mouse ear skin.
[0019] Figure 3 The figures show that P-ATG reduces the pathological changes and inflammatory infiltration of the skin of mice with psoriasis model (n=5, **P<0.01, ***P<0.001); A is the HE staining result of the ear skin of mice in the model group and the treatment group; B is the statistical analysis of the comparison of the thickness of the mouse ear skin layer (Acanthosis); C is the statistical analysis of the infiltration of inflammatory cells (Number of infilteated cells) in the dermis.
[0020] Figure 4 This is the result of ELISA detection of IL-17A secretion in the ear skin of psoriasis mice.
[0021] Figure 5The results of P-ATG inhibiting the secretion of inflammatory cytokine IL-17A after T cell activation in PBMC (n=3, **P<0.01, ***P<0.001). Among them, Ctrl is the control group of healthy human PBMC, PMA+Ion is the group of PBMC stimulated with PMA (final concentration 50ng / mL) plus ionomycin (final concentration 1μg / mL), and PMA+Ion+P-ATG is the group of PBMC pretreated with 10μg / mL P-ATG and then stimulated with PMA and ionomycin.
[0022] Figure 6 Flow cytometry was used to detect the proportion of cells in each group of 293T cells that bound to pig IgG.
[0023] Figure 7 Laser confocal microscopy was used to detect the co-localization of CD127 (red) and porcine IgG (green) in 293T cells.
[0024] Figure 8 After 72h of stimulation with Anti-CD127mAb and IL-7 in advance, the phosphorylation level of STAT5 signal in CD4+T cells was detected by flow cytometry and its proportion was statistically analyzed (n=3-6 per group, *p<0.05, **p<0.01, ***p<0.001). DETAILED DESCRIPTION
[0025] The present invention is further described in detail below in conjunction with specific embodiments so that those skilled in the art can understand the present invention more clearly. The following embodiments are only used to illustrate the present invention, but are not only used to limit the scope of the present invention. Based on the specific embodiments in the present invention, all other embodiments obtained by ordinary technicians in the field without creative work belong to the protection scope of the present invention. In the embodiments of the present invention, unless otherwise specified, all raw material components are commercially available products well known to those skilled in the art; in the embodiments of the present invention, if not specifically specified, the technical means used are conventional means well known to those skilled in the art.
[0026] Sources of key experimental materials and description of physical and chemical indicators:
[0027] P-ATG: 250 mg / 5 mL / bottle, prepared by Wuhan Zhongsheng Yujin Biotechnology Co., Ltd.
[0028] Imiquimod (IMQ): Imiquimod cream 3 g / tube (Mingxinlidi), produced by Sichuan Mingxin Pharmaceutical Co., Ltd.
[0029] Normal porcine IgG: 20 mg / 0.4 mL / bottle, prepared by Wuhan Zhongsheng Yujin Biotechnology Co., Ltd.
[0030] PBS buffer: 500 mL / bottle, product number: SH30256.01, produced by Cytiva.
[0031] Example 1
[0032] This embodiment provides a method for constructing a psoriasis model, which comprises the following steps: C57BL / 6 male mice (purchased from Wuhan Chunyuhong Experimental Animal Feed Co., Ltd., 7-8 weeks old, weighing 20-22 grams) were randomly divided into 3 groups, and the mice received a topical dose of 25 mg of imiquimod (IMQ) applied to each ear every day for 7 consecutive days to construct a psoriasis mouse model.
[0033] The experimental groups included: Control group, IMQ+IgG group (normal IgG control group) and IMQ+P-ATG group (treatment group), with 5 mice in each group.
[0034] In this example, the control group was used as a control, and P-ATG was used to treat the psoriasis mouse model. The specific experimental method included: the model group mice (IMQ+IgG group) were intraperitoneally injected with 50 mg / kg / d normal porcine IgG, and the treatment group (IMQ+P-ATG group) were intraperitoneally injected with 50 mg / kg / d P-ATG, and the drugs were administered continuously for 7 days.
[0035] From the establishment of the model, the thickness of the mouse ears was measured every 2 days until 7 days of drug administration. The mice were scored daily according to the internationally recognized PASI scoring standard. The scoring indicators and scoring standards are as follows:
[0036] ① Skin thickness:
[0037] 0 points: smooth skin without wrinkles;
[0038] 1 point: slight wrinkles appear on the skin at the edge of the application area;
[0039] 2 points: slight wrinkles appear on the skin of the application area;
[0040] 3 points: The wrinkles in the application area are further deepened;
[0041] 4 points: Based on the score of 3, the mice showed weight loss or poor condition.
[0042] ② Scales:
[0043] 0 points: smooth skin without scaling;
[0044] 1 point: slight scaling of the skin in the application area;
[0045] 2 points: The skin in the application area is completely covered with scales;
[0046] 3 points: The degree of scaling in the application area deepens further;
[0047] 4 points: Based on the score of 3, the mice showed weight loss or poor condition.
[0048] ③ Erythema:
[0049] 0 points: smooth skin;
[0050] 1 point: slight redness of the skin in the application area;
[0051] 2 points: The skin in the application area turns completely red;
[0052] 3 points: The red color of the applied area deepens further
[0053] 4 points: Based on the score of 3, the mice showed weight loss or poor condition.
[0054] Cumulative score = skin thickness score + scaling score + and erythema score.
[0055] The ear skin treatment effect and ear thickness measurement results of the experimental mice are shown in Figure 1 .
[0056] Depend on Figure 1 It can be seen that: the ear skin of normal mice had no swelling, redness, and scaling, while the ears of the mice in the model group were obviously swollen, reddened, and covered with a large area of scaling in flaky form. Compared with the model group, the ears of the mice in the P-ATG treatment group were less swollen, and the scaling area and degree were reduced. The results of ear thickness measurement showed that the ear thickness of the P-ATG treatment group was significantly reduced compared with that of the model group, indicating that P-ATG treatment significantly improved the symptoms of psoriasis skin in mice.
[0057] The ear thickness measurement and PASI score results of the experimental mice are shown in Figure 2 .
[0058] Depend on Figure 2 It can be seen that after P-ATG treatment, the ear thickness of psoriasis mice was significantly reduced; the PASI score results showed that the P-ATG treatment group significantly reduced the skin thickness score and cumulative score of psoriasis mice, indicating that P-ATG treatment significantly improved the clinical score of the psoriasis mouse model.
[0059] This example further uses HE staining to detect the effect of P-ATG on ear lesions and inflammatory infiltration in psoriasis model mice. The specific method steps include:
[0060] (1) Sampling: After the model was successfully established and on the 7th day of onset, the mice were euthanized by carbon dioxide, and the ears were dissected out and fixed in 4% paraformaldehyde and then dehydrated: 75% ethanol solution (4h), 85% ethanol solution (2h), 90% ethanol solution (2h), 95% ethanol solution (1h), anhydrous ethanol I (30min) and anhydrous ethanol II (30min) were placed in sequence. Then, the tissues were transparentized: alcohol benzene (20min), xylene I (20min), xylene II (20min), paraffin I (1h), paraffin II (1h), paraffin III (1h) (where I, II, and III represent the same reagents in different bottles). After the transparentization, the tissues were embedded in paraffin, and the wax blocks were cut into thin slices with a thickness of 4μm on a microtome. After the paraffin sections were made, they were stored at room temperature for later use.
[0061] (2) HE staining: Place the above paraffin sections in a constant temperature oven at 60°C for 30 minutes (or overnight at 37°C) to dissolve the wax. Place the sections in xylene I (15 minutes), xylene II (15 minutes), 100% anhydrous ethanol (5 minutes), 95% ethanol (2 minutes), 90% ethanol (2 minutes), 80% ethanol (2 minutes), 70% ethanol (2 minutes), and 1× PBS buffer for washing (3 minutes each time, 3 times in total). Stain with hematoxylin for 3 minutes, wash with 1× PBS buffer, then differentiate with 1% hydrochloric acid alcohol for 3-5 seconds, wash with tap water for 2 minutes, and rinse with eosin for about 2 minutes. The slices were placed in 70% ethanol solution (3 min), 80% ethanol solution (3 min), 90% ethanol solution (3 min), 95% ethanol solution (3 min), 100% anhydrous ethanol I (5 min), 100% anhydrous ethanol II (5 min), xylene I (5 min), and xylene II (5 min) in order to dehydrate and make them transparent, and then dried naturally in a fume hood. After drying, the slices were sealed with neutral gum.
[0062] HE staining results Figure 3 As shown, it was shown that P-ATG treatment significantly reduced the epidermal thickening in the ears of psoriasis mice and inhibited the infiltration of inflammatory cells in the dermis.
[0063] This example further uses ELISA to detect the effect of P-ATG on the secretion of inflammatory cytokines in the ears of psoriasis model mice. The specific experimental method steps include:
[0064] (1) Sampling: After the model was successfully established and on the 7th day of onset, the mice were euthanized by carbon dioxide, and the ears were dissected out. The tissues were minced and homogenized with PBS buffer to prepare tissue homogenate.
[0065] (2) ELISA detection of IL-17A content:
[0066] In this experiment, the mouse IL-17A ELISA kit was used to detect the mouse ear tissue homogenate. The operation steps in the manual were followed. The basic process of the ELISA experiment is as follows: A. Before use, mix all reagents thoroughly to avoid foaming; B. Determine the number of strips required according to the number of experimental wells (blank and standard). Both the sample (including the standard) and the blank should be repeated; C. Sample addition: 100μL / well add the diluted Cytokine standard (standard) to the standard well, 100μL / well add the sample to the sample well, set the blank well, and use Dilution buffer R (1×) instead of the sample and standard; D. Add detection antibody: 50μL / well add the diluted Biotinylated antibody (biotin-labeled antibody). After mixing, cover the plate with a sealing film and incubate at 37℃ for 90min; E. Wash the plate: subtract the liquid in the well, add 300μL / well 1× washing buffer; after staying for 1min, discard the liquid in the well. Repeat 3 times, and dry on filter paper for the last time; F. Add enzyme: Add diluted Streptavidin-HRP (streptavidin-horseradish peroxidase) at 100μL / well. Cover with sealing film and incubate at 37℃ for 30min; G. Wash the plate: Repeat step E; H. Color development: Add TMB at 100μL / well, incubate at 37℃ in the dark for 5-30min, and terminate the reaction after color development for 10min; I. Stop the reaction: Add Stop solution at 100μL / well to terminate the reaction. Read the value at a detection wavelength of 450nm within 10 minutes after termination.
[0067] ELISA test results Figure 4 As shown, it was shown that P-ATG treatment significantly inhibited the secretion of IL-17A in the ear skin of psoriasis model mice.
[0068] Example 2
[0069] In this example, ELISA was used to detect the effect of P-ATG on the secretion of T cell-related inflammatory cytokines, which specifically included the following steps:
[0070] Add anticoagulated blood from healthy volunteers diluted once to the upper layer of Ficoll separation solution (purchased from GE). Centrifuge at room temperature with a brake-free centrifuge at 2000rpm for 45min. Peripheral blood mononuclear cells appear as a white flocculent layer between the plasma and the separation solution. Carefully draw up the cells with a Pasteur pipette. Wash the cells with sterile PBS buffer (5 times the volume of the cell pellet) and centrifuge at 1500rpm for 5min. Wash twice with sterile PBS buffer. Discard the supernatant to obtain PBMC cells.
[0071] The isolated PBMC cells were resuspended in 1640 complete medium containing 10% FBS and the cell concentration was adjusted to 2 × 10 6 Each well was inoculated with 100 μL of the culture medium.
[0072] The experiment was specifically divided into three groups: Control, PMA+Ionomycin+IgG, and PMA+Ionomycin+P-ATG. The Control group was given PBS buffer, and the cells in the stimulation group were stimulated with T cell stimulators PMA (tetradecanoylphorbol acetic acid) and Ionomycin (PMA final concentration was 50 ng / mL, and Ionomycin final concentration was 1 μg / mL). The stimulation group was also given different concentrations of P-ATG and IgG (final concentration was 10 μg / mL), respectively. P-ATG and IgG were added 60 minutes before PMA and Ionomycin stimulation. Each group had three replicates, and a group of IgG controls was added to the stimulation group. The treated cells were placed at 37°C and 5% CO 2 After culturing in the incubator for 24 h, the supernatant was collected.
[0073] This experiment uses the enzyme linked immunosorbent assay (ELISA) kit produced by Beijing Dako Company. The operation steps are carried out according to the instructions. The basic process of the ELISA experiment is as follows: A. Before use, mix all reagents thoroughly to avoid foaming; B. Determine the number of strips required according to the number of experimental wells (blank and standard). Samples (including standards) and blanks should be repeated; C. Sample addition: 100μL / well add diluted Cytokine standard (standard) to the standard well, 100μL / well add sample to the sample well, set up blank well, and use Dilution buffer R (1×) instead of sample and standard; D. Add detection antibody: 50μL / well add diluted Biotinylated antibody (biotin-labeled antibody). After mixing, cover with a sealing film and incubate at 37℃ for 90min; E. Wash the plate: subtract the liquid in the well, add 1× washing buffer at 300μL / well; after staying for 1min, discard the liquid in the well. Repeat 3 times, and dry on filter paper for the last time; F. Add enzyme: Add diluted Streptavidin-HRP (streptavidin-horseradish peroxidase) at 100μL / well. Cover with sealing film and incubate at 37℃ for 30min; G. Wash plate: Repeat step E; H. Color development: Add TMB at 100μL / well, incubate at 37℃ in the dark for 5-30min, and determine the termination of the reaction based on the depth of the color in the well (dark blue). Usually, color development can achieve good results in 10-20min; I. Stop reaction: Add Stopsolution at 100μL / well to stop the reaction quickly. Read the value at a detection wavelength of 450nm within 10 minutes after termination.
[0074] ELISA test results Figure 5 As shown, it was demonstrated that P-ATG inhibited the secretion of IL-17A after T cell activation in vitro.
[0075] Example 3
[0076] In this embodiment, flow cytometry and confocal microscopy were used to detect the binding effect of P-ATG and CD127. The specific method steps included: transfecting HEK293T cells with a CD127 overexpression plasmid (the plasmid was commissioned by Shanghai Jikai Gene Technology Co., Ltd. to construct), and using FITC-labeled anti-pig IgG antibody (goat anti-pig FITC, Thermo Fisher Scientific) to detect the binding of P-ATG to CD127 protein on the surface of HEK293T cells by flow cytometry and immunofluorescence.
[0077] (1) Flow cytometry:
[0078] Mouse spleen cell isolation: 8-week-old female C57 / BL6 mice were selected, killed, and disinfected in 75% alcohol for 5 minutes. The mouse spleen was removed and placed in PBS buffer on ice to remove the fibrous tissue around the spleen. The spleen was ground on a pre-cooled PBS buffer filter membrane. During the grinding process, an appropriate amount of PBS buffer was applied for rinsing, and the fibrous tissue on the filter membrane was discarded. Use a Pasteur pipette to draw the suspension of the ground spleen into a 15mL centrifuge tube and centrifuge at 1500rmp for 10 minutes. Discard the supernatant, add 3 times the cell volume of red blood cell lysis buffer, lyse on ice for 5 minutes, and centrifuge at 1500rmp for 10 minutes. Discard the supernatant, add an appropriate amount of PBS buffer (the amount of washing buffer should usually be at least 5 times the volume of the cell pellet), gently blow to mix, wash the obtained cells once, and centrifuge at 1500rmp for 10 minutes. Discard the supernatant and use RPMI1640 culture medium at 10 6 / mL of inoculum was inoculated into the cell culture plate and the spleen cells were placed in CO 2 Incubate in an incubator for 2 h.
[0079] Collect mouse spleen cells from the cell culture plate, centrifuge at 4°C, 1500 rpm for 5 min, remove the supernatant, wash with 2 mL of sterile PBS, centrifuge at 4°C, 1500 rpm for 5 min, repeat once. Extracellular molecule staining: remove the supernatant, add the working concentration of cell surface antibody working solution, incubate at room temperature in the dark for 45 min. Fixation: centrifuge at 4°C, 1500 rpm for 5 min, discard the supernatant, fix the cells with Fixation Buffer, and fix at room temperature in the dark for 20 min. Permeabilization: centrifuge at 4°C, 1500 rpm for 5 min, discard the supernatant, resuspend with Permeabilization Wash Buffer, centrifuge at 1500 rpm for 5-10 min, discard the supernatant, and repeat this step twice. Intracellular staining: Centrifuge at 4℃, 1500rmp for 5min, discard the supernatant, resuspend in 100μLPermeabilization WashBuffer, add anti-pig IgG antibody labeled with fluorescent antibody FITC (goat anti-pig FITC, PA184624, Thermo Fisher Scientific), and keep at room temperature and away from light for 20min. Centrifuge at 4℃ / 1500rmp for 5min, discard the supernatant, wash twice with 2mL Permeabilization Wash Buffer, centrifuge at 4℃, 1500rmp for 5min, discard the supernatant. Resuspend with 0.5mL Cell Staining Buffer, and analyze on the machine.
[0080] (2) Transfection experiment:
[0081] Plant HEK294T cells in a 24-well plate and start transfection when the cell density reaches 70%. Change the cell medium 2h before transfection. Add 1μL Lip3000 to 25μL serum-free Opti-MEM medium and mix well. Add 1μg plasmid DNA and 1μLP3000 to 25μL serum-free Opti-MEM medium and mix well. Add the diluted plasmid DNA to each tube of diluted Lip3000 and incubate at room temperature for 15min. Add the DNA-lipid complex to the cells, mix well, and culture at 37℃ for 48h.
[0082] (3) Immunofluorescence:
[0083] HEK294T cells were washed with 1 mL of sterile PBS buffer and centrifuged at 250 g for 5 min. The supernatant was removed and resuspended in 2 mL of sterile PBS. After counting the cells, the cell count was adjusted to 1×10 5 pc / mL, and transferred into the confocal culture dish pretreated with poly-L-lysine. 2 Culture for 2 hours to allow HEK294T cells to fully adhere to the wall. Gently remove the supernatant, add 2 mL of sterile PBS to wash, repeat once. Remove the PBS wash solution, add 2 mL of 4% paraformaldehyde solution to fix for 15 minutes. Remove the fixative, add 2 mL of sterile PBS to wash, repeat twice, add PBS protein blocking solution containing 5% BSA, and block for 1 hour at room temperature. Remove the blocking solution, add IgG and P-ATG at working concentrations (dilution ratio of 1:20000, 2.5μg / mL), respectively, and incubate at 37℃ for 45 minutes. Remove the supernatant, add 2 mL of sterile PBS to wash, repeat twice, add FITC-labeled anti-swine IgG fluorescent secondary antibody at working concentrations (dilution ratio of 1:100, PA184624, Thermo Fisher Scientific) and APC-labeled anti-human CD3 fluorescent secondary antibody (dilution ratio of 1:200, OKT3, BioLegend)), and incubate for 1 hour in the dark. The supernatant was removed, and 2 ml of sterile PBS was added for washing, and the washing was repeated once. Anti-fluorescence quenching mounting medium containing DAPI dye was added, and the cells were imaged on a laser confocal microscope.
[0084] Flow cytometry and confocal microscopy results were shown in Figure 6 and Figure 7 As shown, it shows that P-ATG can bind to CD127 protein on the surface of HEK293T cells.
[0085] Example 4
[0086] This example uses flow cytometry to detect the effect of P-ATG on the JAK / STAT5 signaling pathway. The specific scheme includes:
[0087] Mouse splenocyte isolation and activation:
[0088] Eight-week-old female C57 / BL6 mice were selected, killed, and disinfected in 75% alcohol for 5 minutes. The mouse spleen was removed and placed in PBS buffer on ice to remove the fibrous tissue around the spleen. The spleen was ground on a pre-cooled PBS buffer filter membrane. During the grinding process, an appropriate amount of PBS buffer was applied for rinsing, and the fibrous tissue on the filter membrane was discarded. Use a Pasteur pipette to draw the suspension of the ground spleen into a 15mL centrifuge tube and centrifuge at 1500rmp for 10 minutes. Discard the supernatant, add 3 times the cell volume of red blood cell lysis buffer, lyse on ice for 5 minutes, and centrifuge at 1500rmp for 10 minutes. Discard the supernatant, add an appropriate amount of PBS buffer (the amount of washing buffer should usually be at least 5 times the volume of the cell pellet), gently blow to mix, wash the obtained cells once, and centrifuge at 1500rmp for 10 minutes. Discard the supernatant and use RPMI1640 culture medium at 10 6 / mL of inoculum was inoculated into the cell culture plate and the spleen cells were placed in CO 2 Incubate in an incubator for 2 h.
[0089] The experiment was specifically divided into Control group, IL-7 group, IL-7+Anti-CD127 group, IL-7+P-ATG group and IL-7+Anti-CD127+P-ATG group.
[0090] The control group was given PBS buffer, and the cells in the stimulation group were stimulated with IL-7 (ab270065, Abcam, 10μg / mL) for 3 days. The cells in the stimulation group were also given P-ATG or Anti-CD127mAb (ab118527, Abcam) 1 hour before IL-7 stimulation, with the final concentration of 10μg / mL. Three replicate wells were set up in each group, and the cells or culture supernatant were collected. Flow cytometry was used to detect the phosphorylation level of STAT5 in CD4+T cells.
[0091] Flow cytometry results Figure 8 As shown, it was shown that P-ATG inhibited Th17 cell differentiation by binding to CD127 protein and blocking the downstream JAK / STAT signaling pathway.
[0092] In general, the present invention has discovered through a large number of experiments that P-ATG can effectively reduce the disease severity of the classic animal model of psoriasis, can specifically bind to CD127 in vitro, and inhibit the inflammatory activation of Th1 and Th17, thereby achieving the effect of preventing or treating psoriasis.
[0093] The present invention essentially provides a drug for preventing or treating psoriasis, the drug comprising P-ATG, and the dosage form of the drug is preferably at least one of a liquid preparation, a lyophilized powder, a spray, an ointment, and a gel.
[0094] It is necessary to point out that the above embodiments are limited to further elaboration and explanation of the technical solution of the present invention, and are not further limitations of the technical solution of the present invention. The method of the present invention is only a preferred implementation scheme, and is not used to limit the protection scope of the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. Use of P-ATG in the preparation of a drug for treating psoriasis, wherein the P-ATG can inhibit the secretion of IL-17A.
2. The use according to claim 1, characterized in that: The P-ATG can specifically bind to CD127.
3. The use according to claim 1, characterized in that: The P-ATG can target and inhibit the activation of Th1 and Th17.
4. The use according to any one of claims 1 to 3, characterized in that: The P-ATG can block the JAK / STAT5 signaling pathway and inhibit the activation of Th17.
5. The use according to any one of claims 1 to 3, characterized in that: The psoriasis is psoriasis vulgaris, pustular psoriasis, erythrodermic psoriasis or arthritic psoriasis.
Citation Information
Patent Citations
Application of immunoglobulin to manufacturing medicine for treating erythroderma psoriaticum
CN104826108A
Preparation method of COVID-19 porcine-derived immunoglobulin
CN113278067A
Preparation method of anti-human T cell porcine immune globulin and hydroformylated placenta
CN115232783A
